| High-income North America |
| Prevalence |
312 301 (242 878–382 044) |
406 645 (316 939–500 868) |
421 064 (328 142–518 193) |
414992 (323 170–511 232) |
1 631108 (1 272 711–2 004 735) |
| Cases per 100 000 |
1817 (1413–2223) |
1809 (1410–2228) |
1789 (1394–2202) |
1761 (1372–2170) |
1792 (1398–2202) |
| YLD |
56 625 (42 735–71 313) |
75 118 (55 834–96 354) |
77 205 (57 942–99 252) |
74 525 (55 493–94 510) |
296 285 (222 764–374979) |
| Rate per 100 000 |
329 (249–415) |
334 (248–429) |
328 (246–422) |
316 (236–401) |
325 (245–412) |
| Western Europe |
| Prevalence |
306 760 (244 393–366 154) |
407 635 (323 805–486 663) |
398 547 (316 114–476 539) |
394 895 (315 514–472 494) |
1 581 607 (1 257 082–1 888 734) |
| Cases per 100 000 |
1727 (1376–2062) |
1733 (1377–2069) |
1715 (1360–2051) |
1684 (1345–2015) |
1714 (1362–2047) |
| YLD |
58 830 (44 214–76 755) |
79 235 (59 655–103 358) |
77 719 (58 698–102 767) |
76 870 (57 392–100 563) |
306 181 (231 706–397 589) |
| Rate per 100 000 |
331 (249–432) |
337 (254–439) |
334 (253–442) |
328 (245–429) |
332 (251–431) |
| Central Europe, Eastern Europe, and Central Asia |
| Prevalence |
464 555 (372 176–551 946) |
566 007 (456 083–671 043) |
490 842 (396 378–579 410) |
456 221 (369 000–539 606) |
2 085 228 (1 684 719–2 467 164) |
| Cases per 100 000 |
2048 (1641–2434) |
2058 (1658–2440) |
2038 (1646–2406) |
1998 (1616–2363) |
2036 (1645–2409) |
| YLD |
96 975 (74084–123 808) |
123 931 (93 748–158 428) |
108 941 (82 212–141 470) |
100 356 (75 919–129 790) |
450 975 (344 233–576 327) |
| Rate per 100 000 |
428 (327–546) |
451 (341–576) |
452 (341–587) |
440 (333–568) |
440 (336–563) |
| Latin America and the Caribbean |
| Prevalence |
672 585 (546 288–790 809) |
793 565 (640 531–936 587) |
771 280 (620 371–911 461) |
757 768 (609 956–895 890) |
3 170 947 (2 566 782–3 741 437) |
| Cases per 100 000 |
1654 (1343–1944) |
1605 (1295–1894) |
1565 (1259–1850) |
1517 (1221–1794) |
1589 (1286–1875) |
| YLD |
163 130 (122 299–205 398) |
192 502 (141 828–249 593) |
186 842 (138 637–245 523) |
180 520 (133 886–238 899) |
765 956 (572 889–985 737) |
| Rate per 100 000 |
401 (301 –505) |
389 (287–505) |
379 (281–498) |
361 (268–478) |
384 (287–494) |
| Southeast Asia, East Asia, and Oceania |
| Prevalence |
1 989 600 (1 551 695–2 417 553) |
2 388 846 (1 858 076–2 909 389) |
2 366 591 (1 837 990–2 863 620) |
2 342 392 (1 825 186–2 833 713) |
9635177 (7 508 265–1 1 680 166) |
| Cases per 100 000 |
1790 (1396–2175) |
1770 (1377–2156) |
1735 (1348–2100) |
1683 (1311–2036) |
1745 (1360–21 16) |
| YLD |
338 527 (261 223–424 819) |
409 425 (314267–510283) |
406 080 (315 679–509 454) |
400 529 (312 259–498 027) |
1 647 992 (1 282 960–2 052 003) |
| Rate per 100 000 |
305 (235–382) |
303 (233–378) |
298 (231–374) |
288 (224–358) |
299 (232–372) |
| South Asia |
| Prevalence |
8 814255 (6 626 639–10 976 227) |
10915694 (8 235 801–13 631 549) |
10 497 333 (7918 391–13093 706) |
10 172 283 (7 644 114–12 708 838) |
42 491 040 (31 992 788–53 01 1 21 1) |
| Cases per 100 000 |
6247 (4696–7779) |
6093 (4597–7610) |
5903 (4453–7363) |
5717 (4296–7142) |
5990 (4510–7474) |
| YLD |
810 729 (612 510–1 052 819) |
1 038 830 (788 263–1 334037) |
1 020 827 (777147–1 297 493) |
987 227 (753 048–1 252 961) |
4042 934 (3 097 570–5 160 238) |
| Rate per 100 000 |
575 (434–746) |
580 (440–745) |
574 (437–730) |
555 (423–704) |
570 (437–727) |
| Sub-Saharan Africa |
| Prevalence |
3 165 296 (2 481 170–3 837 016) |
3 334 212 (2 597 892–4095 851) |
2 843 521 (2 215 008–3 491 657) |
2 321 894 (1 805 326–2 855 238) |
12 578 273 (9 852 736–15 399 332) |
| Cases per 100 000 |
2455 (1924–2976) |
2261 (1762–2777) |
2179 (1698–2676) |
2099 (1632–2581) |
2279 (1785–2790) |
| YLD |
537 270 (403 404–681 216) |
502 903 (371 463–654997) |
427 855 (318 385–563 513) |
344 876 (257 747–450 141) |
1 978 503 (1 492 394–2 545 605) |
| Rate per 100 000 |
417 (313–528) |
341 (252–444) |
328 (244–432) |
312 (233–407) |
358 (270–461) |
| North Africa and the Middle East |
| Prevalence |
2 095 975 (1 607 222–2 594440) |
2 407 074 (1 843 226–2 986 253) |
2 134977 (1 635 729–2 648 684) |
1 888 277 (1 448 419–2 345 875) |
9 063 331 (6 947 456–11 240448) |
| Cases per 100 000 |
4062 (31 15–5028) |
3896 (2984–4834) |
3773 (2891–4681) |
3596 (2759–4468) |
3853 (2954–4779) |
| YLD |
247 026 (186 292–312 698) |
277 132 (211 358–354 743) |
244 547 (186 614–310 299) |
214982 (164447–274 406) |
1 049 302 (801 194–1 335 594) |
| Rate per 100 000 |
479 (361 –606) |
449 (342–574) |
432 (330–548) |
409 (313–523) |
446 (341–568) |
| Global |
| Prevalence |
18 008 445 (13 909 115–22144997) |
21 463 907 (16 582 655–26 376 300) |
20 163 862 (15 573 910–24 783 030) |
19 007 495 (14 683 193–23 427 643) |
83 209 866 (64448 368–102 067 901) |
| Cases per 100 000 |
3318 (2563–4080) |
3246 (2508–3989) |
3169 (2448–3895) |
3083 (2382–3800) |
3207 (2484–3934) |
| YLD |
2 349 727 (1 817 711–2 945 999) |
2 754 614 (2 1 18 761–3 466 366) |
2 603 898 (2 016 091–3 243 552) |
2 437 342 (1 889 411–3 031 441) |
10 753 999 (8 286 290–13 378933) |
| Rate per 100 000 |
433 (335–543) |
417 (320–524) |
409 (317–510) |
395 (306–492) |
414 (319–516) |
